MicroPort Orthopedics SCHANZ SCREW SELF DRILL, SIZE 4mm, REF 20070057, STERILE R Product Usage...
FDA Device Recall #Z-0043-2018 — Class II — September 18, 2017
Recall Summary
| Recall Number | Z-0043-2018 |
| Classification | Class II — Moderate risk |
| Date Initiated | September 18, 2017 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | MicroPort Orthopedics Inc. |
| Location | Arlington, TN |
| Product Type | Devices |
| Quantity | 48 units |
Product Description
MicroPort Orthopedics SCHANZ SCREW SELF DRILL, SIZE 4mm, REF 20070057, STERILE R Product Usage: MPO Total Hip Systems are indicated for use in total hip arthroplasty for reduction or relief of pain and/or improved hip function in skeletally mature patients with the following conditions: 1. non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, and painful hip dysplasia; 2. inflammatory degenerative joint disease such as rheumatoid arthritis; 3. correction of functional deformity; and, 4. revision procedures where other treatments or devices have failed
Reason for Recall
The item is being recalled due to an inadequate pouch seal. This defect has the potential to lead to a loss of sterile pouch integrity, which could impact the products sterility assurance and may lead to serious adverse events such as infections, both localized and systemic.
Distribution Pattern
Worldwide Distribution - US Nationwide in the states of TX, AL, AZ CO, KS ,ME MO, WB, LA, CA, MD, including PR and the country of CANADA
Lot / Code Information
lot 1723305
Other Recalls from MicroPort Orthopedics Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1133-2026 | Class II | Brand Name: MicroPort Product Name: HIPTURN FE... | Dec 19, 2025 |
| Z-0699-2025 | Class II | EVOLUTION MP FEMORAL COMPONENT CS/CR POROUS SIZ... | Oct 29, 2024 |
| Z-2244-2024 | Class II | EVOLUTION¿ MP Femoral CS/CR Non-Porous Non-p... | May 3, 2024 |
| Z-0275-2023 | Class II | EVOLUTION MP Tibial Bases, Size 2+ LEFT, REF ET... | Oct 28, 2022 |
| Z-0276-2023 | Class II | EVOLUTION MP Tibial Bases, Size 7 LEFT, REF ETP... | Oct 28, 2022 |
Frequently Asked Questions
Sterility recalls for medical devices vary in severity. If you have already had a procedure using a potentially non-sterile device, contact your healthcare provider immediately — you may need monitoring for signs of infection. Symptoms to watch for include fever, redness or swelling at the surgical site, unusual pain, or discharge. For devices that have not yet been used, they should be quarantined and returned to the manufacturer per the recall notice. Non-sterile implants can cause serious infections; early detection and treatment are critical.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.